½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1444443

¼¼°èÀÇ ÅëÁõ °ü¸® ½ÃÀå : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ°ú Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)

Pain Management - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÅëÁõ °ü¸® ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 781¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2029³âÀÇ ¿¹Ãø ±â°£ Áß CAGR 3.59%·Î ¼ºÀåÇϸç, 2029³â±îÁö 931¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

ÅëÁõ °ü¸®- ½ÃÀå

COVID-19´Â Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. º¸°Ç ±â°üÀº ºÀ¼â ±âÁØÀ» ÅëÇØ COVID-19 °¨¿°À» ºÀ¼âÇÏ´Â µ¥ °ü¿©ÇÏ°í ÀÖÀ¸¸ç, ´ëºÎºÐÀÇ ÀÀ±Þ ¼ö¼ú°ú ÀÀ±Þ ¼ö¼úÀº Àü ¼¼°è¿¡¼­ ¿¬±âµÇ¾ú½À´Ï´Ù. Indian Journal of Anesthesia 2020¿¡ µû¸£¸é COVID-19´Â ÁßÀçÀû ÅëÁõ °ü¸® ½Ã¼úÀ» Æ÷ÇÔÇÑ ÅëÁõ Ŭ¸®´Ð¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ´Ù°í ÇÕ´Ï´Ù. Àεµ ¸¶Ãë°ú ÀÇ»ç Çùȸµµ ¸¶Ãë ¹× ÁýÁß Ä¡·á ½Ç½À¿¡ ´ëÇÑ °¡À̵å¶óÀÎÀ» ¹ßÇ¥Çß½À´Ï´Ù. ¶ÇÇÑ Journal of Pain MedicineÀº ÀÌ¹Ì ¸é¿ª¾ïÁ¦ »óÅ¿¡ ÀÖ°í SARS-CoV-2 °¨¿° ¹× ÇÕº´Áõ À§ÇèÀÌ ³ôÀº ȯÀÚ¿¡°Ô °æ¸·¿Ü ºñ½ºÅ×·ÎÀ̵å Áֻ縦 ÅëÇØ ±ÙÄ¡Àû ÅëÁõ¿¡ ´ëÇÑ ºñ½ºÅ×·ÎÀ̵强 °æ¸·¿Ü Áֻ縦 °í·ÁÇÒ ¼ö ÀÖ´Ù°í Á¦¾ÈÇß½À´Ï´Ù. PubMed°¡ ¹ßÇ¥ÇÑ 2022³â 4¿ù µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹°ú ij³ª´ÙÀÇ ¸¸¼º ÅëÁõ ȯÀÚµéÀº ÆÒµ¥¹Í ±â°£ Áß ÅëÁõÀÌ Å©°Ô Áõ°¡ÇÑ °ÍÀ¸·Î °üÂûµÇ¾ú½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹Í ÀÌÈÄ ºÒÇÊ¿äÇÑ º´¿ø ¹æ¹®¿¡ ´ëÇÑ Á¦ÇÑÀÌ Ç®¸®¸é¼­ ¸¸¼º ÅëÁõ ȯÀÚµé »çÀÌ¿¡¼­ È¿°úÀûÀÎ ÅëÁõ °ü¸®°¡ ½ÃÇàµÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ÇöÀç ½ÃÀåÀº ÆÒµ¥¹Í ÀÌÀüÀÇ ¼º°Ý¿¡ µµ´ÞÇÑ °ÍÀ¸·Î °üÂûµË´Ï´Ù.

ÁøÅëÁ¦¸¦ Ä¡·áÀÇ Ã¹ ¹ø° ¼±ÅÃÀ¸·Î »ç¿ëÇÏ´Â ±âÁ¸ »ç¾÷Àº ÅëÁõ °ü¸® ½ÃÀåÀÇ ¼ºÀå¿¡ Å©°Ô ±â¿©ÇØ ¿Ô½À´Ï´Ù. ±×·¯³ª ÃÖ±Ù¿¡´Â Àå±â »ç¿ë¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ºÎÀÛ¿ë¿¡ ´ëÇÑ ÀÌÇصµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ±â±â¸¦ ÀÌ¿ëÇÑ ÅëÁõ °ü¸® ¿ä¹ýÀÇ »ç¿ëÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¼ö¼ú ÈÄ ÅëÁõÀº °¡Àå ÈçÇÑ ÅëÁõ Áß ÇϳªÀÔ´Ï´Ù. ºÎÀÛ¿ëÀ» ¸ð´ÏÅ͸µÇÏ°í Ä¡·áÇÏ´Â µ¥ ºñ¿ëÀÌ ¸¹ÀÌ µé±â ¶§¹®¿¡ ÅëÁõ °ü¸® ¾à¹° ¹× ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ ¸¹½À´Ï´Ù.

ÇöÀç ½ÃÀå¿¡¼­´Â ¿ÀÇÇ¿ÀÀÌµå ¹× ½ÃÀå¿¡¼­ È®¸³µÈ ´Ù¸¥ ÁøÅëÁ¦¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ¾ïÁ¦Çϱâ À§ÇØ ºñ ¿ÀÇÇ¿ÀÀÌµå ¾à¹°ÀÇ Ã¤ÅÃÀÌ Á¡Â÷ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ÀÛ¿ë ¸ÞÄ¿´ÏÁòÀ» °¡Áø ÀϺΠºñ ¿ÀÇÇ¿ÀÀÌµå ¾à¹°Àº ÇöÀç °³¹ß ÃÊ±â ¹× Èı⠴ܰ迡 ÀÖ½À´Ï´Ù. ¿©·¯ ±¹°¡ÀÇ ±ÔÁ¦ ´ç±¹Àº ´ëü Á¢±Ù ¹æ½ÄÀ¸·Î ÀüȯÇÏ°í ÀÖÀ¸¸ç, ±× °á°ú ÀÌ·¯ÇÑ ÀǾàÇ° ½ÃÀå ½ÂÀÎÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ´Ü°èÀûÀ¸·Î ÀÌ·ç¾îÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼­ ÅëÁõ °ü¸®´Â ¿¹Ãø ±â°£ Áß ¹Ù¶÷Á÷ÇÑ ¼ºÀå Àü¸ÁÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

¸¸¼º ÅëÁõÀÇ À¯º´·üÀº ³ëÀÎ Àα¸¿¡¼­ »ó´ëÀûÀ¸·Î ³ôÀ¸¸ç »ç¸Á·üÀÇ µ¶¸³ÀûÀÎ À§Çè ¿ä¼Ò·Î °£ÁֵDZ⠶§¹®¿¡ Àü ¼¼°è °í·ÉÈ­ Àα¸ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦Ç° Ãâ½Ã ¼ö Áõ°¡µµ ½ÃÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 10¿ù Esteve Pharmaceuticals´Â ¹Ì±¹ FDA·ÎºÎÅÍ ¼¼±×·»Æ¼½º(¼¼·¹ÄÛ½Ãºê ¹× Æ®¸£¶ó¸¶µ¹ ¿°»ê¿°)¸¦ ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦¸¦ ÇÊ¿ä·Î ÇÒ Á¤µµ·Î ½É°¢ÇÏ°í ´ëü Ä¡·á¹ýÀÌ ÃæºÐÇÏÁö ¾ÊÀº ¼ºÀÎÀÇ ±Þ¼º ÅëÁõÀ» °ü¸®Çϱâ À§ÇØ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ÅëÁõ °ü¸® ½ÃÀåÀº ¿¹Ãø ±â°£ Áß Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª ÅëÁõ °ü¸® ±â±âÀÇ ³ôÀº ½Ã¼ú ºñ¿ë°ú ±¸¸Å ºñ¿ëÀ¸·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀÌ ¾ïÁ¦µÉ ¼ö ÀÖ½À´Ï´Ù.

ÅëÁõ °ü¸® ½ÃÀå µ¿Çâ

¾È¸éÅëÁõ ¹× ÆíµÎÅë ºÎ¹®Àº ¿¹Ãø ±â°£ Áß »ó´çÇÑ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

µÎÅë°ú ¾È¸é ÅëÁõÀº ÀÀ±Þ½Ç°ú ¿Ü·¡¿¡¼­ ÈçÈ÷ º¼ ¼ö ÀÖ´Â ¸î °¡Áö Áõ»ó Áß ÇϳªÀÔ´Ï´Ù. µÎÅëÀ» È£¼ÒÇÏ´Â ´ëºÎºÐÀÇ È¯ÀÚ´Â ÆíµÎÅë, ±º¹ß¼º µÎÅë, ±äÀ强 µÎÅëÀÇ ¼¼ °¡Áö ÁÖ¿ä µÎÅë ÁõÈıº Áß Çϳª¸¦ ¾Î°í ÀÖ½À´Ï´Ù.

ÆíµÎÅë ¿¬±¸ Àç´ÜÀº 2021³â ÆíµÎÅëÀº ¸Å¿ì ³Î¸® ÆÛÁø ½Å°æ ÁúȯÀ¸·Î ¹Ì±¹¿¡¼­´Â ¾à 3,900¸¸ ¸í, Àü ¼¼°è¿¡¼­ ¾à 10¾ï ¸íÀÇ ³²¼º, ¿©¼º, ¾î¸°ÀÌ°¡ ¾Î°í ÀÖ´Ù°í ¾÷µ¥ÀÌÆ®Çß½À´Ï´Ù. ÆíµÎÅëÀº ¼¼°è¿¡¼­ ¼¼ ¹ø°·Î ÈçÇÑ Áúº´À¸·Î °£Áֵ˴ϴÙ. Ŭ¸®ºí·£µå Ŭ¸®´ÐÀÇ 2021³â ÃֽŠÁ¤º¸¿¡ µû¸£¸é ÆíµÎÅëÀº ¼¼°è¿¡¼­ 6¹ø°·Î Àå¾Ö¸¦ À¯¹ßÇÏ´Â Áúº´À̱⵵ ÇÕ´Ï´Ù. ¹Ì±¹¿¡¼­´Â 10Ãʸ¶´Ù ´©±º°¡°¡ µÎÅëÀ» È£¼ÒÇϸç ÀÀ±Þ½ÇÀ» ¹æ¹®ÇÏ°í ÀÖÀ¸¸ç, ¾à 1,200¸¸ °ÇÀÌ ±Þ¼º ÆíµÎÅë ¹ßÀÛÀ¸·Î º´¿øÀ» ã½À´Ï´Ù. µû¶ó¼­ ÆíµÎÅëÀÇ ³ôÀº À¯º´·üÀº ÇâÈÄ ¼ö³â°£ ÅëÁõ °ü¸® ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ µÎÅë°ú ÆíµÎÅëÀÇ ºÎ´ãÀº Àü ¼¼°è¿¡¼­ µ¿ÀÏÇÑ °ÍÀ¸·Î ¹àÇôÁ³À¸¸ç ÆíµÎÅë/ µÎÅëÀ¸·Î °íÅë¹Þ´Â »ç¶÷µéÀÇ ºñÀ²Àº ³¯·Î Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 1¿ùJAMA ³×Æ®¿öÅ©¿¡ °ÔÀçµÈ ±â»ç¿¡ µû¸£¸é ¹Ì±¹¿¡¼­ ¿©¼ºÀÇ 17.1%, ³²¼ºÀÇ 5.6%°¡ ÆíµÎÅë Áõ»óÀÌ ÀÖ´Ù°íº¸°íÇß½À´Ï´Ù. µû¶ó¼­ ÆíµÎÅëÀÇ ³ôÀº À¯º´·üÀº ÆíµÎÅë Ä¡·á ½ÃÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¿©·¯ ±â¾÷ÀÌ ½ÃÀå¿¡ ½ÅÁ¦Ç°À» Ãâ½ÃÇÏ¿© Á¶»ç ´ë»ó ºÎ¹®ÀÇ ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. 2022³â 2¿ù, Biohaven Pharmaceutical Holding Company Ltd¿Í Pfizer Inc.´Â À¯·´ÀǾàǰû(EMA)ÀÇ ¾à¹°»ç¿ëÀÚ¹®À§¿øȸ(CHMP)°¡ Ä®½ÃÅä´Ñ À¯ÀüÀÚ °ü·Ã ÆéƼµå(CGRP) ¼ö¿ëü ±æÇ×Á¦ÀÎ Rimegepant¿¡ ´ëÇØ ±àÁ¤ÀûÀÎ ÀÇ°ßÀ» äÅÃÇß´Ù°í º¸°íÇß½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ ½ÅÁ¦Ç° Ãâ½Ã¿Í ÅëÁõÀÇ È®»êÀ¸·Î ÀÎÇØ ÀÌ ºÎ¹®Àº ÇâÈÄ ¼ö³â°£ »ó´çÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ ¾ÏÀ¸·Î ÀÎÇÑ ¾È¸éÅëÁõ°ú µÎÅë Áõ°¡´Â ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù.

ºÏ¹Ì°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ¿¹Ãø ±â°£ Áß¿¡µµ ±× ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»ó

ºÏ¹Ì´Â ÅëÁõ °ü¸® ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ°í ÀÖÀ¸¸ç, ±× ¸ÅÃâ¿¡ °¡Àå Å« ±â¿©¸¦ ÇÏ´Â °÷Àº ¹Ì±¹ÀÔ´Ï´Ù. ³ëÀÎ Àα¸ÀÇ Àå±âÀûÀÎ ÅëÁõ °ü¸®¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÅëÁõ °ü¸® ºÐ¾ßÀÇ ¹ßÀü µîÀÇ ¿äÀÎÀÌ ºÏ¹Ì ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ 2022³â PubMed µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹ÀÎÀÇ ¸¸¼º ÅëÁõ À¯º´·üÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â ¸Å³â 5 ¸í Áß 1 ¸íÀÌ ¸¸¼º ÅëÁõÀ¸·Î °íÅë ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ´Â ¹Ì±¹¿¡¼­ °¡Àå ÈçÇÑ ¸¸¼ºÁúȯ Áß ÇϳªÀ̱⠶§¹®¿¡ ¹Ì±¹ Àü¿ª¿¡¼­ ÅëÁõ °ü¸®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ ±¹¼Ò ¸¶Ãë ÅëÁõ ÀÇÇÐ Çùȸ(ASRA)ÀÇ ±ÇÀå »çÇ׿¡ µû¸£¸é ¸¸¼º ¿ÀÇÇ¿ÀÀÌµå ¿ä¹ý ¹× ÅëÁõ ÁßÀç ÀýÂ÷¿¡¼­ ½ºÅ×·ÎÀ̵带 »ç¿ëÇÏ¸é ¸é¿ª ¾ïÁ¦¸¦ À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ¸é¿ª ¾ïÁ¦¸¦ À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ÀϺΠÁúº´°ú ½Î¿ï ±âȸ¸¦ ÃÖ¼ÒÈ­ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¹ÙÀÌ·¯½º °¨¿°. µû¶ó¼­ ¾Õ¼­ ¾ð±Þ ÇÑ ¸ðµç ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß ÅëÁõ °ü¸® ±â±â ¹× ¾à¹°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀüüÀûÀ¸·Î ¹Ì±¹ ÅëÁõ °ü¸® ½ÃÀåÀº ÅëÁõ Àü¹®ÀÇÀÇ Á¸Àç, FDAÀÇ Á¦Ç° ½ÂÀÎ Áõ°¡ Ãß¼¼, ȯÀÚ¿¡°Ô ÅëÁõ °ü¸® ¼­ºñ½º¸¦ Á¦°øÇϱâ À§ÇÑ ÅºÅºÇÑ ÀÎÇÁ¶ó ´öºÐ¿¡ °æÀïÀÌ Ä¡¿­ÇÑ °ÍÀ¸·Î °£Áֵ˴ϴÙ. ¿¹¸¦ µé¾î 2021³â 11¿ù Biohaven Pharmaceutical Holding Company Ltd¿Í Pfizer Inc.´Â ¹Ì±¹ ¿Ü ½ÃÀå¿¡¼­ ¸®¸Þ°ÔÆÇÆ®(Rimegepant)ÀÇ ½ÂÀÎÀ» ¹Þ¾Æ Àü·«Àû »ó¾÷È­ °è¾àÀ» ü°áÇÑ ¹Ù ÀÖ½À´Ï´Ù. Rimegepant´Â ¹Ì±¹¿¡¼­ Nurtec ODT·Î »óÇ°È­µÇ¾î ÀÖÀ¸¸ç, ÀüÁ¶Áõ»ó À¯¹«¿¡ °ü°è¾øÀÌ ÆíµÎÅë ¹ßÀÛÀÇ ±Þ¼º±â Ä¡·á ¹× ¼ºÀÎÀÇ ¹ßÀÛ¼º ÆíµÎÅë ¿¹¹æ Ä¡·á¸¦ ÀûÀÀÁõÀ¸·Î ÇÏ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ¿¹Ãø ±â°£ Áß ºÏ¹Ì¿¡¼­ ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÅëÁõ°ü¸®»ê¾÷ °³¿ä

ÅëÁõ °ü¸® ½ÃÀåÀº °æÀïÀÌ Ä¡¿­ÇÏ¸ç ¿©·¯ ÁÖ¿ä ±â¾÷À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ÅëÁõ °ü¸® ½ÃÀåÀÇ ±âÁ¸ ±â¾÷Àº °­·ÂÇÑ °æÀï Àü·«À» äÅÃÇÏ°í ÀÖÀ¸¸ç, Ä¡¿­ÇÑ °æÀïÀ» À¯¹ßÇÏ°í ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Abbott Laboratories, Johnson & Johnson, Baxter International Inc.(Avante Health Solutions), Becton, Dickinson and Company, Boston Scientific Corporation µîÀÌ ÀÖ½À´Ï´Ù.

±âŸ ÇýÅÃ

  • ¿¢¼¿ Çü½ÄÀÇ ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ù°£ÀÇ ¾Ö³Î¸®½ºÆ® Áö¿ø

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç°ú ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ÃËÁø¿äÀÎ
    • °í·ÉÀÚ Àα¸¿¡¼­ Àå±âÀûÀÎ ÅëÁõ °ü¸®ÀÇ ¼ö¿ä Áõ°¡
    • ¸¸¼º ÅëÁõÀÇ Ä¡·á¿¡¼­ ÅëÁõ °ü¸® ±â±âÀÇ À¯È¿¼ºÀÌ Áõ¸íµÇ°í ÀÖ´Ù.
    • »õ·Î¿î ÅëÁõ °ü¸® ±â±â¿Í ±â¼úÀÇ °³¹ß
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • ÅëÁõ °ü¸® ±â±âÀÇ °¡¿ë¼º°ú »ç¿ë¿¡ °üÇÑ ÀνÄÀÇ °á¿©
    • ÅëÁõ °ü¸® ±â±âÀÇ °í¾×ÀÇ ½Ã¼ú ¹× ±¸ÀÔ ºñ¿ë
  • Porter's Five Forces ºÐ¼®
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀïÀÇ °­µµ

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • ÅëÁõ °ü¸® ¹æ¹ýº°
    • ¾à¹°
      • ¿ÀÇÇ¿ÀÀ̵å
      • ºñ¸¶¾à¼º ÁøÅëÁ¦
      • ºñ½ºÅ×·ÎÀ̵强Ç׿°Áõ¾à(NSAID)
      • ¸¶ÃëÁ¦
      • Ç×°æ·ÃÁ¦
      • Ç׿ì¿ïÁ¦
      • ±âŸ ºñ¸¶¾à¼º ÁøÅëÁ¦
    • ±â±â
      • ½Å°æÀÚ±Ø ±â±â
      • °æÇÇÀû Àü±â ½Å°æÀÚ±Ø(TENS) ±â±â
      • ³ú ¹× ô¼ö ÀÚ±Ø(SCS) ±â±â
      • ÁøÅëÁ¦ ÁÖÀÔ ÆßÇÁ
      • °ñ¼ö°­³» ÁÖÀÔ ÆßÇÁ
      • ¿ÜºÎ ÁÖÀÔ ÆßÇÁ
  • ¿ëµµº°
    • ½Å°æº´Áõ¼º ÅëÁõ
    • ¾Ï ÅëÁõ
    • ¾È¸éÅ롤ÆíµÎÅë
    • ±Ù°ñ°Ý°è ÅëÁõ
    • ±âŸ ¿ëµµ
  • Áö¿ª
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì
      • ºê¶óÁú
      • ¾Æ¸£ÇîƼ³ª
      • ±âŸ ³²¹Ì

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • Abbott Laboratories
    • Baxter International Inc.(Avante Health Solutions)
    • Becton, Dickinson and Company
    • Boston Scientific Corporation
    • Fresenius SE &Co. KGaA
    • Johnson &Johnson
    • Medtronic PLC
    • Novartis AG
    • Endo International PLC
    • Pfizer Inc.

Á¦7Àå ½ÃÀå ±âȸ¿Í ÇâÈÄ µ¿Çâ

KSA 24.03.18

The Pain Management Market size is estimated at USD 78.12 billion in 2024, and is expected to reach USD 93.19 billion by 2029, growing at a CAGR of 3.59% during the forecast period (2024-2029).

Pain Management - Market

The COVID-19 pandemic has impacted healthcare systems across the world. Health agencies were involved in containing coronavirus transmission through lockdown norms, and most elective and non-urgent surgeries were postponed globally. As per the Indian Journal of Anaesthesia 2020, COVID-19 negatively impacted pain clinics, including interventional pain management procedures. The Indian Society of Anaesthesiologists also published guidelines on anesthesia and intensive care practices. Also, the Journal of Pain Medicine suggested that epidural nonsteroid injections for radicular pain can be considered in patients who are already immunosuppressed and at high risk of SARS-CoV-2 infection and complications. As per the April 2022 data published by PubMed, it was observed that people across the United States and Canada suffering from chronic pain witnessed a significant increase in pain during the pandemic. However, following the pandemic, effective pain management is practiced among people suffering from chronic pain, as restrictions on non-essential hospital visits are lifted. Hence, it is observed that the current market has reached a pre-pandemic nature.

The well-established business of using painkiller medications as the first line of treatment has significantly contributed to the growth of the pain management market. However, in recent years, the growing reliance on their long-term use, as well as a better understanding of their side effects, has led to an increase in the use of device-based pain management therapies. Post-operative pain is one of the most common. The cost of monitoring and treating adverse effects creates a significant demand for pain management drugs and devices.

The current market is gradually adopting more non-opioid medications to suppress the addiction to opioids and other well-established painkillers on the market. Several non-opioid drugs with mechanisms of action are currently in the early and late stages of development. The regulatory authorities in multiple countries are shifting to alternative approaches, thus fast-tracking those drugs to market approval. The shift is expected to be gradual. Thus, pain management has desirable growth prospects during the forecast period.

The increasing aging population globally is expected to drive the market's growth, as the prevalence of chronic pain is relatively high among the geriatric population and is considered an independent risk factor for mortality. The increasing number of product launches is also expected to drive the market. For instance, in Octover 2021, Esteve Pharmaceuticals received approval from the US FDA for SEGLENTIS (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Thus, due to such factors, the pain management market is expected to grow significantly over the forecast period.

However, high procedural and purchase costs of pain management devices can restrain the market's growth.

Pain Management Market Trends

Facial Pain and Migraine Segment is Expected to Exhibit a Significant Growth Rate During the Forecast Period

Headache and facial pain are the few frequent complaints in the emergency and outpatient setting. Most patients who present themselves with headaches have one of the following three main headache syndromes: migraine, cluster headache, or tension headache.

The Migraine Research Foundation updated in 2021 that migraine is an extraordinarily prevalent neurological disease, affecting about 39 million men, women, and children in the United States and 1 billion worldwide. Migraine is considered the third-most prevalent illness in the world. According to the Cleveland Clinic update in 2021, migraine is also the sixth-most disabling illness in the world. For every 10 seconds, someone in the United States goes to the emergency room complaining of a headache, and approximately 1.2 million visits are for acute migraine attacks. Hence, the high prevalence of migraine is expected to propel the growth of the pain management market in the coming years.

Furthermore, the burden of headaches and migraine is found to be the same across the world, and every day, the percentage of people suffering from migraine/headaches increases. For instance, according to the article published in the JAMA Network in January 2022, in the United States, 17.1% of women and 5.6% of men reported having migraine symptoms. Thus, the high prevalence of migraine is expected to boost the migraine therapeutics market. Moreover, several companies are launching new products in the market, leading to the growth of the segment studied. In February 2022, Biohaven Pharmaceutical Holding Company Ltd and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. Hence, such new launches and high prevalence of pain, the segment is expected to witness a strong growth in coming years.

In addition, the increasing burden of cancer is also contributing largely to facial pain and headache which is a fueling factor for the segment growth.

North America Captured the Largest Market Share and is Expected to Retain its Dominance During the Forecast Period

North America holds the largest share of the pain management market, with the United States being the most significant contributor to its revenue. Factors such as increasing demand for long-term pain management from the geriatric population and developments in the pain management field are expected to boost the market growth in North America.

Moreover, according to PubMed data from 2022, the prevalence of chronic pain in Americans is increasing. Every year, one out of five people suffers from chronic pain in the region. Since it is one of the most common chronic conditions in the United States, there is a growing demand for pain management across the country. Furthermore, according to the recommendations provided by the American Society of Regional Anesthesia and Pain Medicine (ASRA), chronic opioid therapy and the use of steroids in interventional pain procedures may induce immune suppression, which is very critical as it minimizes the chances of fighting several viral infections. Hence, all the aforesaid factors are expected to increase the demand for pain management devices and drugs over the forecast period.

Overall, the US pain management market is considered highly competitive, primarily due to the significant presence of pain specialist physicians, the increasing trend of product approvals from the FDA, and the robust infrastructure for providing pain management services to patients. For instance, in November 2021, Biohaven Pharmaceutical Holding Company Ltd and Pfizer Inc. formed a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commercialized as Nurtec ODT in the United States and is indicated for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine in adults. Thus, the market is expected to grow significantly in North America over the forecast period.

Pain Management Industry Overview

The pain management market is highly competitive and consists of several major players. The existing players in the pain management market employ strong competitive strategies, leading to intense competition. Some of the key players in the market are Abbott Laboratories, Johnson & Johnson, Baxter International Inc. (Avante Health Solutions), Becton, Dickinson and Company, and Boston Scientific Corporation, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Demand for Long-term Pain Management from the Geriatric Population
    • 4.2.2 Proven Efficacy of Pain Management Devices for the Treatment of Chronic Pain
    • 4.2.3 Development of Novel Pain Management Devices and Techniques
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness About the Availability and Use of Pain Management Devices
    • 4.3.2 High Procedural and Purchase Cost of Pain Management Devices
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 BY Mode of Pain Management
    • 5.1.1 Drugs
      • 5.1.1.1 Opioids
      • 5.1.1.2 Non-narcotic Analgesics
      • 5.1.1.2.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
      • 5.1.1.2.2 Anesthetics
      • 5.1.1.2.3 Anticonvulsants
      • 5.1.1.2.4 Anti-depressants
      • 5.1.1.2.5 Other Non-narcotic Analgesics
    • 5.1.2 Devices
      • 5.1.2.1 Neurostimulation Devices
      • 5.1.2.1.1 Transcutaneous Electrical Nerve Stimulation (TENS) Devices
      • 5.1.2.1.2 Brain and Spinal Cord Stimulation (SCS) Devices
      • 5.1.2.2 Analgesic Infusion Pumps
      • 5.1.2.2.1 Intrathecal Infusion Pumps
      • 5.1.2.2.2 External Infusion Pumps
  • 5.2 By Application
    • 5.2.1 Neuropathic Pain
    • 5.2.2 Cancer Pain
    • 5.2.3 Facial Pain and Migraine
    • 5.2.4 Musculoskeletal Pain
    • 5.2.5 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Baxter International Inc. (Avante Health Solutions)
    • 6.1.3 Becton, Dickinson and Company
    • 6.1.4 Boston Scientific Corporation
    • 6.1.5 Fresenius SE & Co. KGaA
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Medtronic PLC
    • 6.1.8 Novartis AG
    • 6.1.9 Endo International PLC
    • 6.1.10 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦